^
    No biomarker
    Prolymphocytic Leukemia
    alemtuzumab
    Sensitive: A2 - Guideline
    NOTCH1 mutation
    Prolymphocytic Leukemia
    ibrutinib
    Resistant: C3 – Early Trials
    JAK3 mutation
    Prolymphocytic Leukemia
    venetoclax + ruxolitinib
    Sensitive: C3 – Early Trials
    CDKN2A deletion
    Prolymphocytic Leukemia
    alemtuzumab
    Resistant: C4 – Case Studies
    STAT5B N642H
    Prolymphocytic Leukemia
    alemtuzumab
    Resistant: C4 – Case Studies
    TCL1A rearrangement
    Prolymphocytic Leukemia
    alemtuzumab
    Resistant: C4 – Case Studies
    RAD50 Y625
    Prolymphocytic Leukemia
    alemtuzumab
    Resistant: C4 – Case Studies
    ATM D2721N
    Prolymphocytic Leukemia
    alemtuzumab
    Resistant: C4 – Case Studies
    PAK4 deletion
    Prolymphocytic Leukemia
    alemtuzumab
    Resistant: C4 – Case Studies
    BRAF V600E
    Prolymphocytic Leukemia
    alemtuzumab
    Resistant: C4 – Case Studies
    BRAF V600E
    Prolymphocytic Leukemia
    venetoclax
    Resistant: C4 – Case Studies
    BRAF V600E
    Prolymphocytic Leukemia
    dasatinib
    Resistant: C4 – Case Studies
    BRAF V600E
    Prolymphocytic Leukemia
    vemurafenib
    Sensitive: C4 – Case Studies